• 1.

    Singh AK, et al.. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:20852098. doi: 10.1056/NEJMoa065485

  • 2.

    Drüeke TB, et al.. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:20712084. doi: 10.1056/NEJMoa062276

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:20192032. doi: 10.1056/NEJMoa0907845

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Macdougall IC. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephrol 2008; 3:200207. doi: 10.2215/CJN.03840907

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Macdougall IC. Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10:607614. https://doi.org/10.1093/ndt/10.5.607

    • Search Google Scholar
    • Export Citation
  • 6.

    Regidor DL, et al.. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17:11811191. doi: 10.1681/ASN.2005090997

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Wyatt CM, Drüeke TB. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Kidney Int 2016; 90:923925. doi: 10.1016/j.kint.2016.08.016

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am J Physiol Renal Physiol 2010; 298:F1287−F1296. doi: 10.1152/ajprenal.00736.2009

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Haase VH. Oxygen sensors as therapeutic targets in kidney disease. Nephrol Ther 2017; 13 (Suppl 1):S29−S34. doi: 10.1016/j.nephro.2017.01.015

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:54475454. doi: 10.1128/MCB.12.12.5447

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Sugahara M, et al.. Hypoxia-inducible factor and oxygen biology in the kidney. Kidney360 2020; 1:10211031. doi: https://doi.org/10.34067/KID.0001302020

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Li Z-L, et al.. Treatment of renal anemia with roxadustat: Advantages and achievement. Kidney Dis (Basel) 2020; 6:6573. doi: 10.1159/000504850

  • 13.

    Locatelli F, et al.. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 2017; 45:187199. doi: 10.1159/000455166

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Fishbane S, et al.. Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol [published online ahead of print February 10, 2021]. doi: 10.1681/ASN.2020081150; https://jasn.asnjournals.org/content/early/2021/02/09/ASN.2020081150

    • Search Google Scholar
    • Export Citation
  • 15.

    Chen N, et al.. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019; 381:10111022. doi: 10.1056/NEJMoa1901713

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Chertow GM. Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD. ASN Kidney Week 2020 Reimagined. 2020; FR-OR54. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3479290

    • Search Google Scholar
    • Export Citation
  • 17.

    Eckardt K-U Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD. ASN Kidney Week 2020 Reimagined. 2020; TH-OR01. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3441404

    • Search Google Scholar
    • Export Citation
  • 18.

    Provenzano R, et al.. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis. Kidney Int Rep [published online ahead of print December 24, 2020]. doi: 10.1016/j.ekir.2020.12.018; https://www.sciencedirect.com/science/article/pii/S2468024920318519

    • Search Google Scholar
    • Export Citation
  • 19.

    Provenzano R, et al.. Pooled Efficacy and Cardiovascular (CV) Analyses of Roxadustat in the Treatment of Anemia in CKD Patients on and Not on Dialysis. ASN Kidney Week 2020 Reimagined. 2020; FR-OR131. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3275139

    • Search Google Scholar
    • Export Citation
  • 20.

    Kuriyama S, et al.. A new insight into the treatment of renal anemia with HIF stabilizer. Ren Replace Ther 2020; 6:63. doi: https://doi.org/10.1186/s41100-020-00311-x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Coyne DW, et al.. Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia. ASN Kidney Week 2020 Reimagined. 2020; TH-OR04. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3447031

    • Search Google Scholar
    • Export Citation

HIF Stabilizers Get in Sync: Are ESAs Bye Bye Bye?

  • 1 Gonzalo Matzumura, MD, is a nephrology fellow with Washington University School of Medicine, St. Louis, MO.
Restricted access
Save